OncoCyte Co. (NASDAQ:OCX) Shares Acquired by Pura Vida Investments LLC

Pura Vida Investments LLC boosted its stake in OncoCyte Co. (NASDAQ:OCX) by 32.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 654,451 shares of the company’s stock after buying an additional 159,106 shares during the quarter. OncoCyte makes up about 4.9% of Pura Vida Investments LLC’s investment portfolio, making the stock its 9th largest position. Pura Vida Investments LLC owned 3.89% of OncoCyte worth $1,558,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Geode Capital Management LLC lifted its holdings in OncoCyte by 12.2% during the 3rd quarter. Geode Capital Management LLC now owns 103,980 shares of the company’s stock worth $296,000 after buying an additional 11,289 shares in the last quarter. 55.35% of the stock is owned by hedge funds and other institutional investors.

OncoCyte Price Performance

OncoCyte stock opened at $3.21 on Friday. The firm has a 50-day moving average of $2.79 and a 200-day moving average of $2.72. The company has a market cap of $56.02 million, a price-to-earnings ratio of -0.73 and a beta of 0.79. OncoCyte Co. has a one year low of $1.92 and a one year high of $4.75.

OncoCyte (NASDAQ:OCX) last released its earnings results on Monday, March 24th. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.88. The business had revenue of $1.49 million during the quarter, compared to analysts’ expectations of $0.16 million. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. As a group, sell-side analysts expect that OncoCyte Co. will post -2.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on OCX shares. Needham & Company LLC restated a “buy” rating and issued a $4.25 price target on shares of OncoCyte in a research report on Tuesday, March 25th. StockNews.com started coverage on OncoCyte in a research report on Monday, January 13th. They set a “sell” rating for the company. Stephens restated an “equal weight” rating and issued a $4.00 price objective on shares of OncoCyte in a research report on Tuesday, March 25th. Finally, Lake Street Capital initiated coverage on OncoCyte in a report on Friday. They issued a “buy” rating and a $5.00 price target for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $4.56.

Insider Activity

In other news, major shareholder Patrick W. Smith bought 1,077,600 shares of the firm’s stock in a transaction dated Friday, February 7th. The shares were bought at an average price of $2.05 per share, with a total value of $2,209,080.00. Following the completion of the transaction, the insider now owns 2,872,671 shares of the company’s stock, valued at $5,888,975.55. This trade represents a 60.03 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Andrea S. James purchased 97,561 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were acquired at an average cost of $2.05 per share, for a total transaction of $200,000.05. Following the completion of the transaction, the chief financial officer now owns 151,231 shares of the company’s stock, valued at $310,023.55. This trade represents a 181.78 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 1,185,625 shares of company stock valued at $2,430,510. 1.58% of the stock is owned by company insiders.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.